Bone pain is a chronic debilitating feature of sickle cell disease requiring opioid analgesia with a risk of addiction. Angiotensin-converting enzyme inhibition whose benefit was previously reported in the West Indies was tried in a Nigerian cohort and was found to be encouraging.